Roth Capital reaffirms its Neutral rating and $2 price target on ImmunoCellular (AMEX: IMUC) following Q4 results issued Thursday night. The company reported Q4 break even loss, with the Street looking for a loss of $.09 per share.

Analyst Joseph Pantginis commented We are now on the sidelines until more answers regarding ICT-107 materialize, likely at ASCO, and the company's ability to adequately maintain manufacturing and capital needs becomes clear ... IMUC plans to have an end-of-Phase II meeting with the FDA and a meeting with the EMA in summer 2014 and to finalize protocol for the Phase III trial in 3Q14. IMUC plans to begin enrolling patients in the Phase II study of ICT-140 in ovarian cancer later this year and to complete enrollment of the Phase I IST of ICT-121 in recurrent GBM by the end of the year.

For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.

Shares of ImmunoCellular Therapeutics closed at $1.20 yesterday, with a 52 week range of $0.65-$4.00.

Analyst Comments Analyst EPS View FDA

Immunocellular Therapeutics, Ltd. (IMUC) Posts Break Even Q4 LossMarch 13, 2014 4:14 PM